Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis

Arthritis Research

Volumn 2, Issue 2, 2000, Pages 145-153

  Goldbach Mansky, R ^a   Lee, J M ^a   Hoxworth, J M ^a   Smith II, D ^a   Duray, P ^a   Schumacher, H R Jr ^a   Yarboro, C H ^a   Klippel, J ^a   Kleiner, D ^a,a   El Gabalawy, H S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Early synovitis; Erosion; Matrix metalloproteinse 2; Metalloproteinase; Rheumatoid arthritis

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE MARKER; ENZYME ACTIVATION; EROSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; INFLAMMATION; JOINT RADIOGRAPHY; MALE; PROTEIN BLOOD LEVEL; SYNOVITIS; SYNOVIUM; VOLUNTEER;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MIDDLE AGED; SYNOVIAL MEMBRANE; SYNOVITIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 17744371836     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar79     Document Type: Article

References (53)

1. Outcome in rheumatoid arthritis. A 1985 inception cohort study
2. The natural history of rheumatoid arthritis
3. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive?
4. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis
5. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?
6. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium
7. Elevated plasma stromelysin levels in arthritis
8. A study of metalloproteinases in fifty joint fluid specimens
9. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis
10. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis
11. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis
12. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: A potentially useful laboratory marker
13. Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases
14. New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: Destruction from above
15. Matrix metalloproteinases and metastatic cancer
16. Matrix metalloproteinases and metastasis
17. The regulation of neovascularization of matrix metalloproteinases and their inhibitors
18. Matrix metalloproteinase inhibitors
19. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
20. Quantitative zymography: Detection of picogram quantities of gelatinases
21. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
22. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
23. Percutaneous needle biopsy and synovial histology
24. Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium. Comparison with other adhesion molecules
25. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement
26. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice
27. Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9
28. Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines
29. Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter
30. Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator
31. Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis
32. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation
33. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9
34. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages
35. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes
36. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
37. Expression of matrix metalloproteinases during rat skin wound healing: Evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A
38. Complex role of matrix metalloproteinases in angiogenesis
39. Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex
40. The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor
41. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP)
42. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis
43. Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2
44. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
45. Membrane-type-1 matrix metalloproteinase is abundantly expressed in fibroblasts and osteoclasts at the bone-implant interface of aseptically loosened joint arthroplasties in situ
46. The membrane-type-matrix metalloproteinase/matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 system in periprosthetic connective-tissue remodeling in loose total-hip prostheses
47. Expression of gelatinase A and its activator MT1-MMP in the inflammatory periprosthetic response to polyethylene
48. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis
49. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease
50. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid other surrogate markers
51. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer
52. 92kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer
53. Release of gelatinase A during platelet activation mediates aggregation